@article{SchneiderDittrichBoecketal.2016,
  author    = {Schneider, Eberhard and Dittrich, Marcus and B{\"o}ck, Julia and Nanda, Indrajit and M{\"u}ller, Tobias and Seidmann, Larissa and Tralau, Tim and Galetzka, Danuta and El Hajj, Nady and Haaf, Thomas},
  title     = {CpG sites with continuously increasing or decreasing methylation from early to late human fetal brain development},
  series = {Gene},
  volume    = {592},
  journal   = {Gene},
  number    = {1},
  doi       = {10.1016/j.gene.2016.07.058},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-186936},
  pages     = {110-118},
  year      = {2016},
  abstract  = {Normal human brain development is dependent on highly dynamic epigenetic processes for spatial and temporal gene regulation. Recent work identified wide-spread changes in DNA methylation during fetal brain development. We profiled CpG methylation in frontal cortex of 27 fetuses from gestational weeks 12-42, using Illumina 450K methylation arrays. Sites showing genome-wide significant correlation with gestational age were compared to a publicly available data set from gestational weeks 3-26. Altogether, we identified 2016 matching developmentally regulated differentially methylated positions (m-dDMPs): 1767 m-dDMPs were hypermethylated and 1149 hypomethylated during fetal development. M-dDMPs are underrepresented in CpG islands and gene promoters, and enriched in gene bodies. They appear to cluster in certain chromosome regions. M-dDMPs are significantly enriched in autism-associated genes and CpGs. Our results promote the idea that reduced methylation dynamics during fetal brain development may predispose to autism. In addition, m-dDMPs are enriched in genes with human-specific brain expression patterns and/or histone modifications. Collectively, we defined a subset of dDMPs exhibiting constant methylation changes from early to late pregnancy. The same epigenetic mechanisms involving methylation changes in cis-regulatory regions may have been adopted for human brain evolution and ontogeny.},
  language  = {en}
}
@article{LepetaLourencoSchweitzeretal.2016,
  author    = {Lepeta, Katarzyna and Lourenco, Mychael V. and Schweitzer, Barbara C. and Martino Adami, Pamela V. and Banerjee, Priyanjalee and Catuara-Solarz, Silvina and de la Fuente Revenga, Mario and Marc Guillem, Alain and Haider, Mouna and Ijomone, Omamuyovwi M. and Nadorp, Bettina and Qi, Lin and Perera, Nirma D. and Refsgaard, Louise K. and Reid, Kimberley M. and Sabbar, Mariam and Sahoo, Arghyadip and Schaefer, Natascha and Sheean, Rebecca K. and Suska, Anna and Verma, Rajkumar and Vicidomini, Cinzia and Wright, Dean and Zhang, Xing-Ding and Seidenbecher, Constanze},
  title     = {Synaptopathies: synaptic dysfunction in neurological disorders - a review from students to students},
  series = {Journal of Neurochemistry},
  volume    = {138},
  journal   = {Journal of Neurochemistry},
  number    = {6},
  doi       = {10.1111/jnc.13713},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-187509},
  pages     = {785-805},
  year      = {2016},
  abstract  = {Synapses are essential components of neurons and allow information to travel coordinately throughout the nervous system to adjust behavior to environmental stimuli and to control body functions, memories, and emotions. Thus, optimal synaptic communication is required for proper brain physiology, and slight perturbations of synapse function can lead to brain disorders. In fact, increasing evidence has demonstrated the relevance of synapse dysfunction as a major determinant of many neurological diseases. This notion has led to the concept of synaptopathies as brain diseases with synapse defects as shared pathogenic features. In this review, which was initiated at the 13th International Society for Neurochemistry Advanced School, we discuss basic concepts of synapse structure and function, and provide a critical view of how aberrant synapse physiology may contribute to neurodevelopmental disorders (autism, Down syndrome, startle disease, and epilepsy) as well as neurodegenerative disorders (Alzheimer and Parkinson disease). We finally discuss the appropriateness and potential implications of gathering synapse diseases under a single term. Understanding common causes and intrinsic differences in disease-associated synaptic dysfunction could offer novel clues toward synapse-based therapeutic intervention for neurological and neuropsychiatric disorders. In this Review, which was initiated at the 13th International Society for Neurochemistry (ISN) Advanced School, we discuss basic concepts of synapse structure and function, and provide a critical view of how aberrant synapse physiology may contribute to neurodevelopmental (autism, Down syndrome, startle disease, and epilepsy) as well as neurodegenerative disorders (Alzheimer's and Parkinson's diseases), gathered together under the term of synaptopathies. Read the Editorial Highlight for this article on page .},
  language  = {en}
}